FEATURE ARTICLES

Sanofi EVP Weighs In On The Politics Of Drug Pricing
Sanofi EVP Weighs In On The Politics Of Drug Pricing

According to Suresh Kumar, EVP of external affairs at Sanofi, “It is time for a constructive dialogue on drug pricing, but in the context of access, value, and overall healthcare costs.” But where to begin?

More featured articles

ALSO IN THIS MONTH'S ISSUE:

More From Life Science Leader

CUTTING ROOM FLOOR EDITORIAL

More

LIFE SCIENCE TRAINING INSTITUTE COURSES

Identifying and Closing the Training Gap in Clinical Research May 19, 2016
1pm-2:30pm EDT, Online Training
Adverse Event Reporting: Avoiding Common Pitfalls May 25, 2016
10:30am-12pm EDT, Online Training
More training courses

DIGITAL EDITION

2016 CMO LEADERSHIP AWARDS SPECIAL EDITION

BLOGS

  • Tackling Rising Healthcare Costs Requires Less Talk And More Action
    Tackling Rising Healthcare Costs Requires Less Talk And More Action

    Last October when we asked industry thought leaders, “What would be hot for 2016” (see our December 2015 issue), drug pricing was one topic consistently mentioned. Probably not much of a surprise considering the mass media’s fascination with portraying former Turing CEO Martin Shkreli as being everything that’s bad with biopharma. But the reality is that controversy over drug pricing has been around for as long as there have been drugs. So too have been proposed solutions, such as the current ones seeking product-specific transparency regarding R&D and manufacturing costs as well as pricing. What has been lacking, however, is a concerted effort to bring key stakeholders together to discuss broader, systemwide solutions to address rising U.S. healthcare costs.

  • Are You Ready To Go Beyond The Cutting Edge At BIO 2016?
    Are You Ready To Go Beyond The Cutting Edge At BIO 2016?

    Being the 2015 educational planning committee co-chair for BIO provided behind the scenes insights into what makes for a good industry session proposal at BIO. But beyond that I also learned how important it is for those interested in putting together an educational session for a conference to begin the planning process early. So when Bayer’s VP and Head of the company’s east coast innovation center, Chandra Ramanathan, Ph.D., and I sat down at last year’s annual BIO conference to discuss what type of educational session might be needed for BIO 2016, we did so armed with a wealth of wisdom.

  • What Does The Successful Killing Of The Pfizer Allergan Deal Mean?
    What Does The Successful Killing Of The Pfizer Allergan Deal Mean?

    When I wrote the opinion piece on the U.S. government’s successful killing of the planned Pfizer Allergan merger, it was on the heels of a March Editor’s Note on the current state of U.S. corporate taxes. There are those who argue that U.S. companies aren’t seeking to invert due to high U.S. tax rates. And while we can dispute the rationale behind why companies have been seeking to relocate outside the United States, what can’t be debated is that prior to the recent move by the U.S. Department of Treasury to block the practice, inversions were on the rise. Since 1982, 51 U.S. companies have reincorporated in low-tax countries. But more telling is that of these, 20 (inversions) happened in just the past three years, despite 2004 legislation intended to abolish the practice.

More blogs

 UPCOMING EVENTS

BioNetwork East 2016 May 2 - 4, 2016
Orlando, FL
Authoring and Implementing Standard Operating Procedures (SOPs): Best Practices for Success May 3, 2016
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
Surviving a FDA GCP Inspection – Preparation Techniques for Success May 4, 2016
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
More events